943 related articles for article (PubMed ID: 28739427)
21. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
[TBL] [Abstract][Full Text] [Related]
22. None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.
Jeng WJ; Lin CY; Chen JY; Huang CW; Huang CH; Sheen IS
PLoS One; 2012; 7(11):e48217. PubMed ID: 23173032
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
[TBL] [Abstract][Full Text] [Related]
24. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
25. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
[TBL] [Abstract][Full Text] [Related]
26. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
28. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
29. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
[TBL] [Abstract][Full Text] [Related]
31. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
Scherzer TM; Hofer H; Staettermayer AF; Rutter K; Beinhardt S; Steindl-Munda P; Kerschner H; Kessler HH; Ferenci P
J Hepatol; 2011 May; 54(5):866-71. PubMed ID: 21145807
[TBL] [Abstract][Full Text] [Related]
32. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
33. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
[TBL] [Abstract][Full Text] [Related]
34. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
35. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
Halfon P; Bourliere M; Ouzan D; Maor Y; Renou C; Wartelle C; Pénaranda G; Tran A; Botta D; Oules V; Castellani P; Portal I; Argiro L; Dessein A
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):931-5. PubMed ID: 21900787
[TBL] [Abstract][Full Text] [Related]
36. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
[TBL] [Abstract][Full Text] [Related]
37. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
38. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
Bizid S; Bouali R; Ouedrani A; Mrabet A; Ben Abdallah H; Ghazouani E; Abdelli N
Tunis Med; 2016 Jan; 94(1):6-11. PubMed ID: 27525598
[TBL] [Abstract][Full Text] [Related]
40. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms.
Nafari AH; Ayadi A; Noormohamadi Z; Sakhaee F; Vaziri F; Siadat SD; Fateh A
Infect Genet Evol; 2020 Apr; 79():104144. PubMed ID: 31838260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
